ALEX trial
E1995244
UNEXPLORED
The ALEX trial was a pivotal phase III clinical study that compared alectinib with crizotinib as first-line treatment in patients with ALK-positive advanced non–small cell lung cancer, demonstrating superior efficacy and central nervous system control for alectinib.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ALEX trial canonical | 1 |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.